AGP Executive Report
Last update: 6 hours agoMedicines: Biosimilar use across 27 European countries averaged 40.7% in 2024, up from 3.6% in 2014; Liechtenstein was included in the study. Uptake varied widely, with gain-sharing, switching policies and prescribing quotas linked to faster adoption. Reproductive Health: Prince Alois vetoed Liechtenstein’s abortion bill, saying it did not adequately protect unborn life. It is the first time he has used his veto, leaving campaigners frustrated after parliament approved the proposal. Cancer Treatment: The EU medicines committee recommended RASONQUE, an oral treatment for some adults with previously treated metastatic pancreatic cancer. The European Commission must still decide whether to authorize it.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.